SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 06/08/2006 -- Novacea, Inc. (NASDAQ: NOVC) announced today preliminary results from a Phase 1/2 clinical trial of its investigational product candidate, DN-101 (calcitriol), in second line treatment of non-small cell lung cancer (NSCLC).
